title: Metastatic castration-resistant prostate cancer: two case reports of dramatic response with abiraterone acetate in patients heavily pretreated with chemotherapy.
abstract: Metastatic castration-resistant prostate cancer (mCRPC) with visceral involvement requires new, effective and safe treatments after chemotherapy failure. The CYP17A1 inhibitor abiraterone acetate has been approved as a treatment for mCRPC, both after docetaxel chemotherapy and more recently for patients who are not responding to chemotherapy. In published studies, most patients previously treated with docetaxel had received a limited number of lines of chemotherapy and a small proportion of these patients presented with visceral metastases. We report two mCRPC patients with extensive visceral disease, who were heavily pretreated with chemotherapy. They experienced major responses to treatment with abiraterone acetate. For both patients, responses to abiraterone were noticeable within 1 month, encompassing a marked regression of visceral metastases and a decrease in prostate-specific antigen. The clinical benefit of abiraterone was maintained for at least 6 months and the treatment was well tolerated.
authors.affiliation: Groupe Hospitalier Mutualiste - Institut Daniel Hollard, Service d'Oncologie Médicale, France.
authors.forename: Laura
authors.initials: L
authors.lastname: Dupuy
authors.forename: Jérôme
authors.initials: J
authors.lastname: Long
authors.forename: Yves
authors.initials: Y
authors.lastname: Ranchoup
keywords: Abiraterone acetate; Chemotherapy; Metastatic castration-resistant prostate cancerCytochrome P450 c17; Prostate-specific antigen
references.citation: BJU Int. 2005 Dec;96(9):1241-6
references.pmid: 16287438
references.citation: Cancer Res. 2008 Jun 1;68(11):4447-54
references.pmid: 18519708
references.citation: J Med Chem. 1995 Jun 23;38(13):2463-71
references.pmid: 7608911
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: J Clin Endocrinol Metab. 2012 Feb;97(2):507-16
references.pmid: 22170708
references.citation: J Clin Oncol. 2011 Sep 20;29(27):3651-8
references.pmid: 21859989
references.citation: Ann Oncol. 2012 Apr;23(4):1044-52
references.pmid: 22373539
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references.pmid: 16278481
references.citation: Lancet Oncol. 2012 Oct;13(10):983-92
references.pmid: 22995653